- Home
- NBY vs GRI Comparison
NBY vs GRI Comparison
Compare NBY & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- GRI
- Stock Information
- Founded
- NBY 2000
- GRI 2018
- Country
- NBY United States
- GRI United States
- Employees
- NBY N/A
- GRI N/A
- Industry
- NBY
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- GRI Health Care
- Exchange
- NBY Nasdaq
- GRI Nasdaq
- Market Cap
- NBY 3.5M
- GRI 3.2M
- IPO Year
- NBY 2007
- GRI N/A
- Fundamental
- Price
- NBY $0.61
- GRI $1.37
- Analyst Decision
- NBY Strong Buy
- GRI Strong Buy
- Analyst Count
- NBY 1
- GRI 2
- Target Price
- NBY $0.85
- GRI $22.00
- AVG Volume (30 Days)
- NBY 32.4K
- GRI 110.6K
- Earning Date
- NBY 08-12-2025
- GRI 08-13-2025
- Dividend Yield
- NBY N/A
- GRI N/A
- EPS Growth
- NBY N/A
- GRI N/A
- EPS
- NBY 0.57
- GRI N/A
- Revenue
- NBY $9,781,000.00
- GRI N/A
- Revenue This Year
- NBY $23.91
- GRI N/A
- Revenue Next Year
- NBY $32.05
- GRI N/A
- P/E Ratio
- NBY $1.34
- GRI N/A
- Revenue Growth
- NBY 20.52
- GRI N/A
- 52 Week Low
- NBY $0.36
- GRI $1.10
- 52 Week High
- NBY $2.45
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- NBY 54.61
- GRI 46.93
- Support Level
- NBY $0.58
- GRI $1.20
- Resistance Level
- NBY $0.62
- GRI $1.41
- Average True Range (ATR)
- NBY 0.03
- GRI 0.09
- MACD
- NBY 0.00
- GRI 0.03
- Stochastic Oscillator
- NBY 55.71
- GRI 68.00
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.